60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

<p>Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated from standard of care treatment WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/60-degrees-pharmaceuticals-study-results-published-by-new-microbes-and-new-infections-demonstrate-tafenoquine-exhibits-broad-spectrum-antifungal-activity/">60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>